ascending dose

ascending dose

The administration of increasing doses of a drug until a desired effect is achieved.
References in periodicals archive ?
In addition, Hapten Sciences is planning a multiple ascending dose study in individuals that are sensitive to poison ivy.
Further to the phase 1a single ascending dose stage that reported positive results in April 2015, this phase 1b multiple ascending dose stage was conducted in 24 healthy subjects divided into three groups with each taking active or placebo once a day for 14 days.
Multiple ascending dose study of RPL554 in healthy volunteers completed successfully; excellent tolerability at all dose levels tested
The two E2609 Phase I studies presented at the AAIC 2012 comprised a single oral ascending dose study (Study A001-001) which showed Abeta levels reduction in plasma, and a 14-day multiple oral ascending dose study (Study A001-002) which showed dose-dependent increase of E2609 PK level and statistically significant reduction of Abeta levels in cerebrospinal fluid (CSF).
Both single ascending dose and multiple ascending dose Phase I studies of ICA-105665 have been completed.
In a Phase I single ascending dose, double blind placebo controlled randomized study, all doses of PI-2301 were safe and well tolerated, and no serious adverse events were observed.
The Phase I trial of V24343, a CB1 antagonist, will be a double-blind, randomized, placebo-controlled study in overweight and mildly obese volunteers and will be conducted in two parts: a single ascending dose followed by a multiple ascending dose.
The TAFA93 Phase Ia single center, randomized, placebo-controlled, Single Ascending Dose (SAD) trial began in July 2004.
The study comprised six ascending dose groups each given CDP-791 intravenously once every three weeks.
The recently completed multiple ascending dose study has confirmed the excellent safety and pharmacokinetic profile of GKT137831 in healthy subjects, initially shown in the single ascending dose study completed earlier this year.
16, 2015 /PRNewswire/ -- Turing Pharmaceuticals AG, a privately-held biopharmaceutical company focused on developing and commercializing innovative treatments for serious diseases and conditions, today announced dosing of the first group of subjects in the TUR-004 single ascending dose study, the first clinical study in a comprehensive program aimed at obtaining approval for the treatment of epileptic encephalopathies.